Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Centogene N.V. - Common Shares
(NQ:
CNTG
)
0.3250
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Aug 7, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Centogene N.V. - Common Shares
< Previous
1
2
3
Next >
CENTOGENE Closes Strategic Transaction with Private Equity Group Charme Capital Partners
March 12, 2025
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Announces Voting Results of Extraordinary General Meeting
December 04, 2024
Approval of All Resolutions, Including Announced Transaction With Charme Capital Partners
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Signs Strategic Transaction With Private Equity Group Charme Capital Partners
November 13, 2024
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Data on Novel Genetic Risk Factor for Parkinson’s Disease in The Lancet Neurology
September 25, 2024
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Receives Delisting Notice From Nasdaq
August 07, 2024
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Publication in Brain Journal Reveals 15% of Parkinson’s Disease Cases Are Linked to Genetic Factors
August 01, 2024
From
Centogene NV
Via
GlobeNewswire
C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development
June 20, 2024
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General Meeting
May 31, 2024
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Reports Full Year 2023 Financial Results and Recent Business Highlights
May 15, 2024
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Secures Approx. $20 Million to Strengthen Cash Position
May 15, 2024
Expanding Relationship With Lifera, a Biopharma Company Owned by the PIF
From
Centogene NV
Via
GlobeNewswire
CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease
May 14, 2024
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse Patients
May 10, 2024
Fueling the diagnosis of over 2,500 rare and neurodegenerative diseases, more than 300 peer-reviewed publications, and 48 pharma collaborations
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Receives Nasdaq Non-Compliance Notice
April 02, 2024
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
March 19, 2024
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα Deficiency
February 29, 2024
Complete Pre-TCRα Deficiency Found to be Very Rare, Partial Form More Common Than Expected
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing
February 28, 2024
Notice of Delisting Will Not Immediately Result in the Suspension or Delisting of the Company’s Securities
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Explores Strategic Alternatives
February 28, 2024
From
Centogene NV
Via
GlobeNewswire
CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration
January 25, 2024
Aims to Leverage Diversified Data to Accelerate and De-Risk Drug Discovery and Clinical Development
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Receives French Research Tax Credit Accreditation
January 24, 2024
Partners able to claim up to 30% tax relief
From
Centogene NV
Via
GlobeNewswire
CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics
January 23, 2024
Collaboration to accelerate research to determine role of GBA gene
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Announces Preliminary Full Year 2023 Revenue
January 18, 2024
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Announces Voting Results of Extraordinary General Meeting
December 19, 2023
From
Centogene NV
Via
GlobeNewswire
CENTOGENE’s Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone
December 13, 2023
From
Centogene NV
Via
GlobeNewswire
CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture Transaction
November 28, 2023
From
Centogene NV
Via
GlobeNewswire
CENTOGENE, University College London, and Global Team of Researchers Discover Gene Associated With New Neurodevelopmental Disease Linked to Early-Onset Dystonia and Parkinsonism
November 14, 2023
Results From Landmark Study Published in Brain Journal
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Expands Multiomic Diagnostic Portfolio With Newly-Launched Transcriptomic Offering
October 10, 2023
Incorporating RNA sequencing provides better diagnostics to enable a more complete understanding of disease biology
From
Centogene NV
Via
GlobeNewswire
CENTOGENE to Present at H.C. Wainwright 25th Annual Global Investment Conference
September 11, 2023
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Reports First Half 2023 Financial Results
September 07, 2023
Strong Revenues and Steady Growth in Both Diagnostics and Pharma Segments Drive Sustainable Financial Performance
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Announces Publication Establishing Lyso-Gb1 as a Predictive Biomarker for Gaucher Disease Patients
September 01, 2023
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Receives Nasdaq Non-Compliance Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency
August 31, 2023
From
Centogene NV
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
